Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 2/2014

01.02.2014 | 2013 SSAT Plenary Presentation

Overexpressing TNF-Alpha in Pancreatic Ductal Adenocarcinoma Cells and Fibroblasts Modifies Cell Survival and Reduces Fatty Acid Synthesis via Downregulation of Sterol Regulatory Element Binding Protein-1 and Activation of Acetyl CoA Carboxylase

verfasst von: Mazhar Al-Zoubi, Galina Chipitsyna, Shivam Saxena, Konrad Sarosiek, Ankit Gandhi, Christopher Y. Kang, Daniel Relles, Jocelyn AndrelSendecki, Terry Hyslop, Charles J. Yeo, Hwyda A. Arafat

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

The effect of tumor necrosis factor-alpha (TNF-α) gene delivery has been suggested as a potentially useful therapeutic approach to improve the chemotherapeutic treatment of patients with pancreatic ductal adenocarcinoma (PDA), but the exact mechanism of its action is not clearly understood. In this study, we analyzed the expression profile of TNF-α in PDA tissue and explored its potential role in fatty acid synthase (FAS) regulation in PDA cells and in fibroblasts. Quantitative real-time polymerase chain reaction was used to examine the expression of TNF-α in PDA, matching adjacent tissues, and benign lesions. Logistic regression models with robust variance were used to analyze the gene expression levels, and Kaplan–Meier survival curves were generated. In vitro, we overexpressed the TNF-α gene in PDA cells and fibroblasts and analyzed its effect on cell survival, migration, and on members of the FAS signaling pathway. We also evaluated TNF-α effects on a panel of inflammation-, angiogenesis-, and metastasis-related markers. In the tumor tissue of PDA patients, compared with their matched adjacent tissue, expression levels of TNF-α were not statistically different and did not correlate with survival or any other examined clinicopathological features. Overexpression of TNF-α significantly (p < 0.05) reduced PDA and fibroblast cell migration. In PDA cells that highly overexpress TNF-α, this was associated with a significant reduction of FAS mRNA and protein expression levels and significant (p < 0.05) reduction of SREBP-1 and ACC mRNA. Reduction of FAS by TNF-α was inhibited when either SREBP-1 or ACC was knocked down by siRNA. PDA cells and fibroblasts that overexpress TNF-α displayed differential regulation of several inflammation-related markers and reduced levels of metastasis-related genes. Our data demonstrate a previously unknown multi-targeted involvement of TNF-α in PDA lipogenesis and inflammation and metastasis and suggest that intratumoral introduction of TNF-α may have the potential as a novel therapeutic approach in human PDA.
Literatur
1.
Zurück zum Zitat A. Jemal, R. Siegel, E. Ward et al. Cancer statistics, 2010. CA Cancer J Clin, 58 (2010), pp. 71–96CrossRef A. Jemal, R. Siegel, E. Ward et al. Cancer statistics, 2010. CA Cancer J Clin, 58 (2010), pp. 71–96CrossRef
2.
Zurück zum Zitat Schneider G., Siveke JT, Eckel F. et al. Pancreatic cancer: basic and clinical aspects Gastroenterology, 128 (2005), pp. 1606–1625PubMedCrossRef Schneider G., Siveke JT, Eckel F. et al. Pancreatic cancer: basic and clinical aspects Gastroenterology, 128 (2005), pp. 1606–1625PubMedCrossRef
3.
Zurück zum Zitat Moertel CG, Frytak S., Hahn RG et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group Cancer, 48 (1981), pp. 1705–1710PubMedCrossRef Moertel CG, Frytak S., Hahn RG et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group Cancer, 48 (1981), pp. 1705–1710PubMedCrossRef
4.
Zurück zum Zitat Burris 3rd HA, Moore MJ, Andersen J. et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol, 15 (1997), pp. 2403–2413PubMed Burris 3rd HA, Moore MJ, Andersen J. et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol, 15 (1997), pp. 2403–2413PubMed
5.
Zurück zum Zitat Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood 2012; 119:651–65.PubMedCrossRef Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood 2012; 119:651–65.PubMedCrossRef
6.
Zurück zum Zitat Roberts NJ, Zhou S, Diaz LA, Holdhoff M. Systemic use of tumor necrosis factor alpha as an anticancer agent. Oncotarget 2011; 2:739–51PubMed Roberts NJ, Zhou S, Diaz LA, Holdhoff M. Systemic use of tumor necrosis factor alpha as an anticancer agent. Oncotarget 2011; 2:739–51PubMed
7.
Zurück zum Zitat Bevilacqua MP, Stengelin S., Gimbrone Jr. MA, et al. Endothelial leukocyte adhesion molecule 1: an inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science, 243 (1989), pp. 1160–1165PubMedCrossRef Bevilacqua MP, Stengelin S., Gimbrone Jr. MA, et al. Endothelial leukocyte adhesion molecule 1: an inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science, 243 (1989), pp. 1160–1165PubMedCrossRef
8.
Zurück zum Zitat Carswell EL, Old LJ, Kassel RL, et al. An endotoxin induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA, 72 (1975), pp. 3666–3670PubMedCrossRef Carswell EL, Old LJ, Kassel RL, et al. An endotoxin induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA, 72 (1975), pp. 3666–3670PubMedCrossRef
9.
Zurück zum Zitat Mauceri HJ, Hanna NN, Wayne JD, et al.Tumor necrosis factor alpha (TNF-alpha) gene therapy targeted by ionizing radiation selectively damages tumor vasculature. Cancer Res, 56 (1996), pp. 4311–4314PubMed Mauceri HJ, Hanna NN, Wayne JD, et al.Tumor necrosis factor alpha (TNF-alpha) gene therapy targeted by ionizing radiation selectively damages tumor vasculature. Cancer Res, 56 (1996), pp. 4311–4314PubMed
10.
Zurück zum Zitat Staba MJ, Mauceri HJ, Kufe DW, et al.Adenoviral TNF-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft. Gene Ther, 5 (1998), pp. 293–300PubMedCrossRef Staba MJ, Mauceri HJ, Kufe DW, et al.Adenoviral TNF-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft. Gene Ther, 5 (1998), pp. 293–300PubMedCrossRef
11.
Zurück zum Zitat Al-Zoubi M, Salem AF, Martinez-Outschoorn UE, et al. Creating a tumor-resistant microenvironment: cell-mediated delivery of TNFα completely prevents breast cancer tumor formation in vivo. Cell Cycle. 2013 Feb 1;12(3):480–90. Al-Zoubi M, Salem AF, Martinez-Outschoorn UE, et al. Creating a tumor-resistant microenvironment: cell-mediated delivery of TNFα completely prevents breast cancer tumor formation in vivo. Cell Cycle. 2013 Feb 1;12(3):480–90.
12.
Zurück zum Zitat Kuhajda, FP, Piantadosi, S, Pasternack, GP. Haptoglobin-related protein (Hpr) epitopes in breast cancer as a predictor of recurrence of the disease. N. Engl. J. Med. 1989;321:636–641.PubMedCrossRef Kuhajda, FP, Piantadosi, S, Pasternack, GP. Haptoglobin-related protein (Hpr) epitopes in breast cancer as a predictor of recurrence of the disease. N. Engl. J. Med. 1989;321:636–641.PubMedCrossRef
13.
Zurück zum Zitat Kuhajda, FP, Jenner K, Wood FD, et al. Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc. Natl Acad. Sci. USA. 1994;91: 6379–6383.PubMedCrossRef Kuhajda, FP, Jenner K, Wood FD, et al. Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc. Natl Acad. Sci. USA. 1994;91: 6379–6383.PubMedCrossRef
14.
Zurück zum Zitat Jackowski, S. Coordination of membrane phospholipid synthesis with cell cycle. J. Biol. Chem. 1994; 269:3858–3867.PubMed Jackowski, S. Coordination of membrane phospholipid synthesis with cell cycle. J. Biol. Chem. 1994; 269:3858–3867.PubMed
15.
Zurück zum Zitat Costello, LC, Franklin RB. Tumor cell metabolism: the marriage of molecular genetics and proteomics with cellular intermediary metabolism; proceed with caution. Molecular Cancer. 2006;5:59.PubMedCentralPubMedCrossRef Costello, LC, Franklin RB. Tumor cell metabolism: the marriage of molecular genetics and proteomics with cellular intermediary metabolism; proceed with caution. Molecular Cancer. 2006;5:59.PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat Costello, LC, Franklin RB. "Why do tumour cells glycolyse"?: from glycolysis through citrate to lipogenesis. Mol. Cell. Biochem. 2005;280:1–8.PubMedCrossRef Costello, LC, Franklin RB. "Why do tumour cells glycolyse"?: from glycolysis through citrate to lipogenesis. Mol. Cell. Biochem. 2005;280:1–8.PubMedCrossRef
17.
Zurück zum Zitat Alo PL, Amini M, Piro F, et al. Immunohistochemical expression and prognostic significance of fatty acid synthase in pancreatic carcinoma. Anticancer Res. 2007;27(4B):2523–7.PubMed Alo PL, Amini M, Piro F, et al. Immunohistochemical expression and prognostic significance of fatty acid synthase in pancreatic carcinoma. Anticancer Res. 2007;27(4B):2523–7.PubMed
18.
Zurück zum Zitat Walter K, Hong SM, Nyhan S, et al. Serum fatty acid synthase as a marker of pancreatic neoplasia. Cancer Epidemiol Biomarkers Prev. 2009;18(9):2380–5.PubMedCentralPubMedCrossRef Walter K, Hong SM, Nyhan S, et al. Serum fatty acid synthase as a marker of pancreatic neoplasia. Cancer Epidemiol Biomarkers Prev. 2009;18(9):2380–5.PubMedCentralPubMedCrossRef
19.
Zurück zum Zitat Horiguchi A, Asano T, Asano T, et al. Fatty acid synthase over expression is an indicator of tumor aggressiveness and poor prognosis in renal cell carcinoma. J Urol. 2008;180(3):1137–40.PubMedCrossRef Horiguchi A, Asano T, Asano T, et al. Fatty acid synthase over expression is an indicator of tumor aggressiveness and poor prognosis in renal cell carcinoma. J Urol. 2008;180(3):1137–40.PubMedCrossRef
20.
Zurück zum Zitat Silva SD, Perez DE, Nishimoto IN, et al. Fatty acid synthase expression in squamous cell carcinoma of the tongue: clinicopathological findings. Oral Dis. 2008;14(4):376–82.PubMedCrossRef Silva SD, Perez DE, Nishimoto IN, et al. Fatty acid synthase expression in squamous cell carcinoma of the tongue: clinicopathological findings. Oral Dis. 2008;14(4):376–82.PubMedCrossRef
21.
Zurück zum Zitat Ogino S, Nosho K, Meyerhardt JA, et al. Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol. 2008;10;26(35):5713–20PubMedCrossRef Ogino S, Nosho K, Meyerhardt JA, et al. Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol. 2008;10;26(35):5713–20PubMedCrossRef
22.
Zurück zum Zitat Menendez, JA, Vellon L, Colomer R, Lupu R. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity. Int. J. Cancer. 2005;115:19–35.PubMedCrossRef Menendez, JA, Vellon L, Colomer R, Lupu R. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity. Int. J. Cancer. 2005;115:19–35.PubMedCrossRef
23.
Zurück zum Zitat Lupu, R. & Menendez, J. A. Pharmacological inhibitors of fatty acid synthase (FASN)-catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents? Curr. Pharm. Biotechnol. 2006;7: 495–502.PubMedCrossRef Lupu, R. & Menendez, J. A. Pharmacological inhibitors of fatty acid synthase (FASN)-catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents? Curr. Pharm. Biotechnol. 2006;7: 495–502.PubMedCrossRef
24.
Zurück zum Zitat Pizer ES, Thupari J, Han WF, et al. Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res. 2000;60:213–218.PubMed Pizer ES, Thupari J, Han WF, et al. Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res. 2000;60:213–218.PubMed
25.
Zurück zum Zitat De Schrijver E, Brusselmans K, Heyns W, et al. RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res. 2003;63:3799–3804.PubMed De Schrijver E, Brusselmans K, Heyns W, et al. RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res. 2003;63:3799–3804.PubMed
26.
Zurück zum Zitat Barber MD, Powell JJ, Lynch SF, et al. Two polymorphisms of the tumour necrosis factor gene do not influence survival in pancreatic cancer. Clin Exp Immunol. 1999 Sep;117(3):425–9. Barber MD, Powell JJ, Lynch SF, et al. Two polymorphisms of the tumour necrosis factor gene do not influence survival in pancreatic cancer. Clin Exp Immunol. 1999 Sep;117(3):425–9.
27.
Zurück zum Zitat Talar-Wojnarowska R, Gasiorowska A, Smolarz B, et al. Tumor necrosis factor alpha and interferon gamma genes polymorphisms and serum levels in pancreatic adenocarcinoma. Neoplasma. 2009;56(1):56–62.PubMedCrossRef Talar-Wojnarowska R, Gasiorowska A, Smolarz B, et al. Tumor necrosis factor alpha and interferon gamma genes polymorphisms and serum levels in pancreatic adenocarcinoma. Neoplasma. 2009;56(1):56–62.PubMedCrossRef
28.
Zurück zum Zitat Zhang L, Wu G, Herrle F, et al. Single nucleotide polymorphisms of genes for EGF, TGF-β and TNF-α in patients with pancreatic carcinoma. Cancer Genomics Proteomics. 2012 Sep-Oct;9(5):287–95. Zhang L, Wu G, Herrle F, et al. Single nucleotide polymorphisms of genes for EGF, TGF-β and TNF-α in patients with pancreatic carcinoma. Cancer Genomics Proteomics. 2012 Sep-Oct;9(5):287–95.
29.
Zurück zum Zitat Karayiannakis AJ, Syrigos KN, Polychronidis A, et al. Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients. Anticancer Res. 2001 Mar-Apr;21(2B):1355–8. Karayiannakis AJ, Syrigos KN, Polychronidis A, et al. Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients. Anticancer Res. 2001 Mar-Apr;21(2B):1355–8.
30.
Zurück zum Zitat Hardie DG, Carling D, Carlson M. The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell? Annu Rev Biochem. 1998;67:821–855.PubMedCrossRef Hardie DG, Carling D, Carlson M. The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell? Annu Rev Biochem. 1998;67:821–855.PubMedCrossRef
31.
Zurück zum Zitat Winder WW, Hardie DG: The AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol. 1999;277:E1-E10PubMed Winder WW, Hardie DG: The AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol. 1999;277:E1-E10PubMed
32.
33.
Zurück zum Zitat Moore RJ, Owens DM, Stamp G, et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med. 1999Jul; 5(7):828–31 Moore RJ, Owens DM, Stamp G, et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med. 1999Jul; 5(7):828–31
34.
Zurück zum Zitat Popivanova BK, Kitamura K, Wu Y, et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest. 2008 Feb;118(2):560–70. Popivanova BK, Kitamura K, Wu Y, et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest. 2008 Feb;118(2):560–70.
35.
Zurück zum Zitat Egberts JH, Cloosters V, Noack A, et al. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res. 2008 Mar 1;68(5):1443–50. Egberts JH, Cloosters V, Noack A, et al. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res. 2008 Mar 1;68(5):1443–50.
36.
Zurück zum Zitat Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer. 2009 May;9(5):361–71. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer. 2009 May;9(5):361–71.
37.
Zurück zum Zitat Ariapart P, Bergstedt-Lindqvist S, van Harmelen V, et al. Resection of pancreatic cancer normalizes the preoperative increase of tumor necrosis factor alpha gene expression. Pancreatology. 2002;2(5):491–4.PubMedCrossRef Ariapart P, Bergstedt-Lindqvist S, van Harmelen V, et al. Resection of pancreatic cancer normalizes the preoperative increase of tumor necrosis factor alpha gene expression. Pancreatology. 2002;2(5):491–4.PubMedCrossRef
38.
Zurück zum Zitat Pikarsky E, Porat RM, Stein I, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004 Sep 23;431(7007):461–6. Pikarsky E, Porat RM, Stein I, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004 Sep 23;431(7007):461–6.
39.
Zurück zum Zitat Il'yasova D, Colbert LH, Harris TB, et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2413–8. Il'yasova D, Colbert LH, Harris TB, et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2413–8.
40.
Zurück zum Zitat Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol. 2004 Dec;14(6):433–9. Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol. 2004 Dec;14(6):433–9.
41.
Zurück zum Zitat Raz Y, Erez N. An inflammatory vicious cycle: Fibroblasts and immune cell recruitment in cancer. Exp Cell Res. 2013 Apr 5. doi:pii: S0014-4827(13)00130-4 Raz Y, Erez N. An inflammatory vicious cycle: Fibroblasts and immune cell recruitment in cancer. Exp Cell Res. 2013 Apr 5. doi:pii: S0014-4827(13)00130-4
42.
Zurück zum Zitat Iyengar P, Espina V, Williams TW, et al. Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J Clin Invest 2005; 115:1163–76;PubMedCentralPubMed Iyengar P, Espina V, Williams TW, et al. Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J Clin Invest 2005; 115:1163–76;PubMedCentralPubMed
43.
Zurück zum Zitat Williams TM, Medina F, Badano I, et al. Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem 2004; 279:51630–46PubMedCrossRef Williams TM, Medina F, Badano I, et al. Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem 2004; 279:51630–46PubMedCrossRef
44.
Zurück zum Zitat Siddiqui A, Jones E, Andrade D, et al. Osteopontin splice variant as a potential marker for metastatic disease in pancreatic adenocarcinoma. Clinical Gastroentrology. In Press. Siddiqui A, Jones E, Andrade D, et al. Osteopontin splice variant as a potential marker for metastatic disease in pancreatic adenocarcinoma. Clinical Gastroentrology. In Press.
45.
Zurück zum Zitat Rodrigues LR, Teixeira JA, Schmitt FL, et al. The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1087–97 Rodrigues LR, Teixeira JA, Schmitt FL, et al. The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1087–97
46.
Zurück zum Zitat Gong Q, Davis M, Chipitsyna G, et al. Blocking angiotensin II Type 1 receptor triggers apoptotic cell death in human pancreatic cancer cells. Pancreas. 2010 Jul;39(5):581–94. Gong Q, Davis M, Chipitsyna G, et al. Blocking angiotensin II Type 1 receptor triggers apoptotic cell death in human pancreatic cancer cells. Pancreas. 2010 Jul;39(5):581–94.
Metadaten
Titel
Overexpressing TNF-Alpha in Pancreatic Ductal Adenocarcinoma Cells and Fibroblasts Modifies Cell Survival and Reduces Fatty Acid Synthesis via Downregulation of Sterol Regulatory Element Binding Protein-1 and Activation of Acetyl CoA Carboxylase
verfasst von
Mazhar Al-Zoubi
Galina Chipitsyna
Shivam Saxena
Konrad Sarosiek
Ankit Gandhi
Christopher Y. Kang
Daniel Relles
Jocelyn AndrelSendecki
Terry Hyslop
Charles J. Yeo
Hwyda A. Arafat
Publikationsdatum
01.02.2014
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 2/2014
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-013-2370-7

Weitere Artikel der Ausgabe 2/2014

Journal of Gastrointestinal Surgery 2/2014 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.